Anaplastic Large Cell Lymphoma Therapeutics Market
Global Anaplastic Large Cell Lymphoma Therapeutics Market Size, Share and Trend Analysis Report, By Disease Type (Primary ALCL and Relapsed ALCL), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Stem Cell Transplant, and Medications), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global anaplastic large cell lymphoma therapeutics market is anticipated to grow at a considerable CAGR during the forecast year. Anaplastic large-cell lymphoma (ALCL) is a rare type of bold cancer and it is most common among teenagers, especially boys. One of the major factors that are augmenting the growth of the anaplastic large cell lymphoma therapeutics market is growing effective treatment through radiation therapy. According to a report published by the national cancer institute in 2020, radiation therapy was first used to treat cancer more than 100 years ago and nearly half of all cancer patients get some relaxation during their treatment. Radiation treatment brings radiation from outside the body to kill tumors inside the body. Radiation therapy at the cellular level has the potential to reduce the risk of both short-term and long-term side effects of treatment while at the same time customizing even small deposits of cancer cells to be killed throughout the body.
Impact of COVID-19 on Global Anaplastic Large Cell Lymphoma Therapeutics Market
COVID-19 Pandemic had impacted the global economy due to a slowdown in the manufacturing of various industries. The diagnosis and cancer screening of various cancer diseases had also been postponed during the COVID-19 pandemic as non-urgent procedures were given the least preference by the authorities. Moreover, lockdowns restrictions resulted as a major factor for the decline in the growth of the anaplastic large cell lymphoma therapeutics treatment market.
Segmental Outlook
The global anaplastic large cell lymphoma therapeutics market is segmented based on disease type and treatment type. Based on disease type, the market is sub-segmented into primary ALCL and relapsed ALCL. Based on treatment type, the market is sub-segmented into surgery, radiation therapy, chemotherapy, stem cell transplant, and medications.
Global Anaplastic Large Cell Lymphoma Therapeutics Market by Treatment Type, 2021(%)
The Stem Cell Transplant Segment is Anticipated to Hold a Major Share in the Global Anaplastic Large Cell Lymphoma Therapeutics market.
Stem cell transplants are procedures that restore blood stem cells to individuals who have been destroyed by high doses of chemotherapy or radiation used to treat certain cancers. Stem cell transplantation is a common term that encompasses several different techniques such as the transplantation of allogeneic hemopoietic stem cells, which is the form of bone marrow, peripheral blood, or umbilical cord of a healthy donor that would be matched for HLA type treatment. Additionally, ALK-negative ALCL patients are provided with effective treatment with stem cell transplant after remission, and this is more common in patients over 55 years of age.
Regional Outlooks
The global anaplastic large cell lymphoma therapeutics market is further segmented based on geography including North America (US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The Asia-Pacific region is expected to have a significant share in the global anaplastic large cell lymphoma therapeutics market due to the presence of several key players in the region and the increasing genetic population.
Global Anaplastic Large Cell Lymphoma Therapeutics Market Growth by Region, 2022-2028
The North America Region is Expected to Grow at a Significant CAGR in the Global Anaplastic Large Cell Lymphoma Therapeutics Market During Forecast Year.
North American region holds the major share and is anticipated to grow fastest during the forecast period in the anaplastic large cell lymphoma therapeutics market. The increasing number of patients suffering from cancer is acting as the important factor driving the growth of the market in the region. According to United Nations Population Funds (UNFPA), cancer is the leading cause of death in Canada and the second leading cause, after heart disease, in the US. Approximately 1.9 million new cancer cases and around 693,000 cancer deaths occur in North America in 2019. Common prostate cancer in men and breast cancer in women, while lung cancer remains the most common cause of cancer in both. ?
Market Players Outlook
The major companies serving the global anaplastic large cell lymphoma therapeutics market include Arcturus Therapeutics Holdings Inc., BLR Bio LLC., CTI Biopharma Corp., Novartis AG, Prolong Pharmaceuticals LLC., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, fundings, and new product launches. For instance, In September 2021, Soligenix, Inc., which is considered as one of the late-stage biopharmaceutical companies that are focused on developing and commercializing products to treat rare diseases had set forth that the Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) had approved orphan drug designation in order to active ingredient hypericin for the treatment of T-cell lymphoma.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global anaplastic large cell lymphoma therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on The Global Anaplastic Large Cell Lymphoma Therapeutics Market
Recovery Scenario of Global Anaplastic Large Cell Lymphoma Therapeutics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Arcturus Therapeutics Holdings Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. BLR Bio LLC.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. CTI Biopharma Corp.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novartis AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Prolong Pharmaceuticals LLC.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Anaplastic Large Cell Lymphoma Therapeutics Market by Disease Type
4.1.1. Primary ALCL
4.1.2. Relapsed ALCL
4.2. Global Anaplastic Large Cell Lymphoma Therapeutics Market by Treatment Type
4.2.1. Surgery
4.2.2. Radiation Therapy
4.2.3. Chemotherapy
4.2.4. Stem Cell Transplant
4.2.5. Medications
5. Regional Analysis
5.1. North America
5.1.1. The US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AmbioPharm, Inc.
6.2. Amgen Inc.
6.3. AstraZeneca plc.
6.4. Corbus Pharmaceuticals, Inc.
6.5. Daiichi Sankyo Co.
6.6. Dr.Reddys Laboratories, Ltd.
6.7. GlaxoSmithKline plc
6.8. Idera Pharmaceuticals, Inc.
6.9. Johnson & Johnson Services, Inc.
6.10. Kerxy Biopharmaceuticals Inc.
6.11. Kissei Pharmaceuticals Co. Ltd.
6.12. Octapharma AG
6.13. Takeda Pharmaceuticals Co. Ltd.
6.14. Viatris Inc.
1. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
2. GLOBAL PRIMARY ALCL IN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL RELAPSED ALCL IN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
5. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN STEM CELL TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN MEDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
14. EUROPEAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
16. EUROPEAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
20. REST OF THE WORLD ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET, 2022-2028 (%)
4. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SHARE BY DISEASE TYPE, 2021 VS 2028 (%)
5. GLOBAL PRIMARY ALCL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL RELAPSED ALCL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SHARE BY TREATMENT TYPE, 2021 VS 2028 (%)
8. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN SURGERY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN RADIATION THERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN CHEMOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN STEM CELL TRANSPLANT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS IN MEDICATIONS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
16. UK ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD ANAPLASTIC LARGE CELL LYMPHOMA THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
